Cosibelimab: A New Option for Cutaneous Squamous Cell Carcinoma With Matthew Hadfield, DO

Cosibelimab, a novel programmed cell death protein 1 (PD-1) inhibitor, has received FDA approval for treating unresectable, locally advanced, or metastatic cutaneous squamous cell carcinoma (CSCC). This milestone offers new hope for patients facing significant challenges due to this aggressive form of skin cancer.

Challenges in Cutaneous Squamous Cell Carcinoma

Cutaneous squamous cell carcinoma is the second most common type of skin cancer in the United States. While most cases are treated successfully through surgical resection, advanced cases can lead to high morbidity and mortality. Approximately 15,000 individuals in the US succumb to CSCC annually, highlighting the urgent need for effective systemic therapies.

Significance of Cosibelimab

Dr. Matthew Hadfield, a medical oncologist at Brown University, emphasized the importance of this approval: “Cosibelimab provides an important new option for patients with advanced or metastatic CSCC who have limited local treatment options. The 47% response rate observed in the trial is significant, especially for this patient population.”

Clinical Evidence and Key Findings from CK-301-101

The approval was based on results from the CK-301-101 trial, a multicenter, open-label phase 1 study that enrolled 109 patients with advanced CSCC unsuitable for surgery or radiation. Patients received 800 mg of cosibelimab every two weeks until disease progression or intolerable side effects.

The study revealed the following outcomes:

1. Overall response rate (ORR): A 47% response rate was observed, as evaluated by blinded independent review
2. Consistency across subgroups: Response rates were consistent among patients with metastatic and unresectable disease
3. Durable responses: At the 17.7-month data cutoff, the median duration of response had not yet been reached, indicating the potential for long-lasting efficacy

Dr. Hadfield noted, “The durability of responses is particularly encouraging, as it suggests that many patients may achieve sustained benefit with this treatment.”

Key Takeaways for Oncology Fellows

1. Expanded treatment landscape: Cosibelimab represents a critical addition to the therapeutic arsenal for advanced CSCC, providing an alternative mechanism of action compared to other PD-1 inhibitors
2. Trial insights: The CK-301-101 trial highlights the drug’s efficacy and tolerability in a challenging patient population, although its exclusion criteria (eg, autoimmune disease and recent organ transplantation) should be considered when selecting candidates
3. Future directions: As data mature, the long-term benefits and safety profile of cosibelimab will become clearer, potentially establishing it as a cornerstone therapy for advanced CSCC

The FDA approval of cosibelimab underscores the progress in immunotherapy for skin cancers, offering hope for improved outcomes in patients with limited treatment options.

About Dr. Hadfield

Matthew Hadfield, DO, is a Medical Oncologist at Brown University/Legorreta Cancer Center, with a pending faculty appointment at the Warren Alpert School of Medicine of Brown University. He recently completed his Hematology/Oncology Fellowship at Brown University. Dr. Hadfield’s clinical and research interests are in phase 1 clinical trials and developmental therapeutics, as well as cutaneous malignancies and immunotherapy-related adverse events.